All News

At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.

European exchanges are opening back up for riskier ventures, and experts expect the trend to continue. But trade-sales should still dominate, says Mary Lisbeth D'Amico.

8.8 per cent: The proportion of GDP that OECD countries spend on health.

Cambridge University is tightening its grip on rights to intellectual property generated by staff and students after academics voted overwhelmingly to endorse new plans

IP2IPO Group, which specialises in commercialising university technology, has made an exclusive 25-year deal with the University of Bristol to form spin-out companies from the university. Analysts greeted the deal as a boost for the company.

Microsoft is to open more research centres in Europe, in a move to step up its research collaboration and boost students' interest in the technology field.

What are stem cells, what could they do - and why are investors wary of putting their money in them? A lay guide to the technology

Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.

The European Commission's Clinical Trials Directive was meant to make trials more simple. But it looks as if the effect has been to stop many trials taking place at all.

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.